PUBLISHER: Acute Market Reports | PRODUCT CODE: 1255979
PUBLISHER: Acute Market Reports | PRODUCT CODE: 1255979
GI Stool Testing Market Is Projected to Expand At A CAGR Of XX% Between 2023 And 2031. Stools tests are performed to diagnose GI tract disorders and aid in the detection of parasites infection, bleeding obstruction, and inflammation. Stools tests can further be utilized for the diagnosis of colorectal cancer or the presence of pathogens such as Rotavirus, C. difficile, H. pylori among others in the GI tract. Laboratory tests used for stool testing are either microbial particle-based or antibody-based, which include chemiluminescence immunoassays (CLIA), immunoassays, and molecular diagnostic testing.
Increased incidence of C. difficile infections and other gastrointestinal diseases increases the demand for stool tests, thereby driving the global GI stool testing market. According to the Centers for Disease Control and Prevention, in 2014, an estimated of 14.8 million adults were diagnosed with ulcers and other digestive disorders in the United States. Furthermore, in 2017, 135,430 new cases of colorectal cancer were diagnosed in the country, raising the demand for GI stool testing. However, the challenge of accurate testing restrains the market.
The global GI stool testing market is segmented based on product type, application, test type, end-user, and geography. Among product types, the reagents segment dominated the global market in 2017 with over 60% of the market share. Among applications, the GI tract infections segment led the global market in 2022 owing to high prevalent cases and increased awareness regarding gastrointestinal disorders. Based on end-users, hospitals will continue to dominate the market owing to the high procedural load of the tests.
North America is anticipated to lead the global market owing to the high awareness of gastrointestinal disorders and the availability of evolved healthcare infrastructure. Manufacturers are focusing on emerging markets including the Asia Pacific and Latin America due to the presence of potential opportunities.
Key Players Identified in GI Stool Testing Market include:
BioMrieux Inc, Meridian Bioscience Inc, DiaSorin S.p.A., Beckman Coulter Inc., Alere Inc., Bio Rad Laboratories, Cenogenics Corporation, Siemens Healthcare, Quest Diagnostics Incorporated, Abbott Laboratories and Others.
Historical & Forecast Period
This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2031.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of GI Stool Testing market are as follows:
Research and development budgets of manufacturers and government spending
Revenues of key companies in the market segment
Number of end users and consumption volume, price and value.
Geographical revenues generate by countries considered in the report:
Micro and macro environment factors that are currently influencing the GI Stool Testing market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Product
Reagents
Instruments
Application
Colorectal Cancer
Diarrhea
GI Tract Infections
Others (Poor Absorption Problems, Parasites)
Test Type
Microscopy Tests
Culture Tests
Ova & Parasites Test
Occult Blood test
Immuno-FOB ELISA Test
Lateral Flow Immuno-FOB Test
Immuno-FOB agglutination test
Guaiac FOB Stool Test
Stool Biomarkers Tests
M2-PK Stool Test
Cologuard
Others (FIT (Fecal Immunochemical Test), Stool Fat Testing)
End-user
Hospitals
Diagnostics Centers and Laboratories
Research Centers and Academic Institutions
Region Segment (2021-2031; US$ Million)
North America
U.S.
Canada
Rest of North America
UK and European Union
UK
Germany
Spain
Italy
France
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC
Africa
Rest of Middle East and Africa
Key questions answered in this report:
What are the key micro and macro environmental factors that are impacting the growth of GI Stool Testing market?
What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
Estimated forecast and market projections up to 2031.
Which segment accounts for the fastest CAGR during the forecast period?
Which market segment holds a larger market share and why?
Are low and middle-income economies investing in the GI Stool Testing market?
Which is the largest regional market for GI Stool Testing market?
What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
Which are the key trends driving GI Stool Testing market growth?
Who are the key competitors and what are their key strategies to enhance their market presence in the GI Stool Testing market worldwide?